Quick Answer
CytomX Therapeutics, Inc. reported Cash and Equivalents of $12.67 million for fiscal year 2025.
CytomX Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $12.67M | -66.7% |
| 2024 | $38.05M | +121.6% |
| 2023 | $17.17M | -91.1% |
| 2022 | $193.65M | -5.8% |
| 2021 | $205.53M | +7.1% |
| 2020 | $191.86M | +1.8% |
| 2019 | $188.43M | -23.9% |
| 2018 | $247.58M | +39.4% |
| 2017 | $177.55M | +69.7% |
| 2016 | $104.64M | +74.9% |
| 2015 | $59.82M | -7.1% |
| 2014 | $64.40M | +639.9% |
| 2013 | $8.70M | -41.0% |
| 2012 | $14.75M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $34.19M | -15.8% | -30.3% |
| June 30, 2025 | $49.04M | +13.4% | +3.0% |
| March 31, 2025 | $47.60M | +31.6% | +25.1% |
| December 31, 2024 | $38.05M | +121.6% | -6.2% |
| September 30, 2024 | $40.58M | +55.9% | -6.2% |
| June 30, 2024 | $43.25M | -24.8% | +19.5% |
| March 31, 2024 | $36.19M | -35.8% | +110.7% |
| December 31, 2023 | $17.17M | -91.1% | -34.0% |
- CytomX Therapeutics, Inc. showed a decrease of -66.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, CytomX Therapeutics, Inc.’s cash and equivalents has declined by 14.1% (from $14.75 million to $12.67 million).
- The most recent figure is from CytomX Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: